Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 4/20 | 0.54 |
| ▸ | CDC25A | P30304 | 3/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | PTPRC | P08575 | 2/20 | 0.50 |
| ▸ | GAPDH | P04406 | 1/20 | 0.47 |
| ▸ | S100A4 | P26447 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | NSD2 | O96028 | 2/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14399370 | 0.81 | CYP19A1 (0.46) | CDC25BCDC25AIDO1GAPDHMEN1 | |
| SCHEMBL29771457 | 0.80 | PTPRC (0.77) | CDC25BCDC25AIDO1PTPRCGAPDH | |
| SCHEMBL8473068 | 0.80 | PTPRC (0.77) | CDC25BCDC25AIDO1PTPRCGAPDH | |
| SCHEMBL29800450 | 0.77 | CDC25B (0.74) | CDC25BCDC25AIDO1PTPRCGAPDH | |
| SCHEMBL2511730 | 0.77 | CDC25B (0.74) | CDC25BCDC25AIDO1PTPRCGAPDH | |
| SCHEMBL6052850 | 0.77 | CDC25B (0.56) | CDC25BCDC25AIDO1PTPRCGAPDH | |
| SCHEMBL28463389 | 0.75 | CDC25B (0.53) | CDC25BCDC25AIDO1PTPRCGAPDH | |
| SCHEMBL9628358 | 0.74 | CDC25B (0.61) | CDC25BCDC25AIDO1PTPRCGAPDH | |
| SCHEMBL9713967 | 0.74 | CDC25B (0.61) | CDC25BCDC25AIDO1PTPRCGAPDH | |
| SCHEMBL11246332 | 0.74 | CDC25B (0.56) | CDC25BCDC25AIDO1PTPRCGAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3284464-B1 | COMPOSITION FOR PREVENTING AND TREATING PANCREATITIS CONTAINING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT | NADIANBIO LTD (KR) | 2025-08-13 | — | — | EP | disclosed |
| US-12370170-B2 | Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment | NADIANBIO LTD. (KR) | 2025-07-29 | — | — | US | disclosed |
| EP-3449920-B1 | COMPOSITION COMPRISING DUNNIONE OR BETA-LAPACHONE AS ACTIVE INGREDIENT, FOR PREVENTING OR AMELIORATING FATIGUE, PAIN, COGNITIVE DECLINE AND HEMATOPOIETIC STEM CELL REDUCTION WHICH ARE SIDE EFFECTS RELATED TO ANTICANCER DRUG TREATMENT | NADIANBIO LTD (KR) | 2025-05-28 | — | — | EP | disclosed |
| US-12257230-B2 | Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment | NADIANBIO LTD. (KR) | 2025-03-25 | — | — | US | disclosed |
| US-20230372286-A1 | COMPOSITION COMPRISING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT, FOR PREVENTING OR AMELIORATING FATIGUE, CACHEXIA, PAIN, COGNITIVE DECLINE AND HEMATOPOIETIC STEM CELL REDUCTION WHICH ARE SIDE EFFECTS RELATED TO ANTICANCER DRUG TREATMENT | NADIANBIO LTD. (KR) | 2023-11-23 | — | — | US | disclosed |
| CN-107530316-B | Composition for preventing and treating pancreatitis containing naphthoquinone-based compound as active ingredient | （株）娜迪安生物公司 | 2020-08-25 | — | — | CN | disclosed |
| US-20200155500-A1 | COMPOSITION FOR PREVENTING AND TREATING PANCREATITIS CONTAINING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT | NADIANBIO LTD. (KR) | 2020-05-21 | — | — | US | disclosed |
| US-20190083453-A1 | COMPOSITION COMPRISING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT, FOR PREVENTING OR AMELIORATING FATIGUE, CACHEXIA, PAIN, COGNITIVE DECLINE AND HEMATOPOIETIC STEM CELL REDUCTION WHICH ARE SIDE EFFECTS RELATED TO ANTICANCER DRUG TREATMENT | NADIAN BIO LTD. (KR) | 2019-03-21 | — | — | US | disclosed |
| CN-109414427-A | Composition for preventing or improving fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell depletion as side effects associated with anticancer drug treatment comprising naphthoquinone-based compound as active ingredient | （株）娜迪安生物公司 | 2019-03-01 | — | — | CN | disclosed |
| US-20180098960-A1 | COMPOSITION FOR PREVENTING AND TREATING PANCREATITIS CONTAINING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT | NADIANBIO LTD. (KR) | 2018-04-12 | — | — | US | disclosed |
| US-5969163-A | CONTACTING SOLUTION OF LAWSONE IN DIMETHYL SULFOXIDE AT LOW TEMPERATURE WITH LITHIUM HYDRIDE AND WARMING TO FORM LITHIUM SALT, ALKYLATING WITH ALLYL HALIDE IN PRESENCE OF LITHIUM IODIDE, CYCLIZING ALKYLATED LAWSONE DERIVATIVES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-10-19 | — | — | US | disclosed |
| US-5962002-A | 1,1,4,4-SUBSTITUTED DIHYDRONAPHTHALENE COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
| EP-0759898-B1 | NAPHTHOQUINONE DERIVATIVES | BTG INT LTD (GB) | 1999-07-14 | — | — | EP | disclosed |
| EP-0802730-B1 | PESTICIDAL COMPOUNDS | BTG INT LTD (GB) | 1999-06-23 | — | — | EP | disclosed |
| US-5834515-A | PESTICIDE; TREATING WITH A PLANT EXTRACT FROM A CALCEOLARIA SPECIES | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1998-11-10 | — | — | US | disclosed |
| US-5824700-A | ANTICARCINOGENIC AGENTS FOR TREATING BREAST CANCER OR COLON CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1998-10-20 | — | — | US | disclosed |
| EP-0802730-A1 | PESTICIDAL COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 1997-10-29 | — | — | EP | disclosed |
| EP-0759898-A1 | NAPHTHOQUINONE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 1997-03-05 | — | — | EP | disclosed |
| WO-1996021355-A1 | PESTICIDAL COMPOUNDS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1996-07-18 | — | — | WO | disclosed |
| WO-1995032176-A1 | NAPHTHOQUINONE DERIVATIVES | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12257230-B2 | Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment | IL17A, ACHE, IL1B | CDC25B 174/4885CDC25A 97/4885IDO1 1918/4885 |
| US-12370170-B2 | Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment | ACHE, NES, GSTO1 | CDC25B 356/4885CDC25A 236/4885IDO1 3195/4885 |
| US-20180098960-A1 | COMPOSITION FOR PREVENTING AND TREATING PANCREATITIS CONTAINING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT | PNLIP, AMY2A, SERPINB1 | CDC25B 1998/4885CDC25A 991/4885IDO1 2230/4885 |
| US-20190083453-A1 | COMPOSITION COMPRISING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT, FOR PREVENTING OR AMELIORATING FATIGUE, CACHEXIA, PAIN, COGNITIVE DECLINE AND HEMATOPOIETIC STEM CELL REDUCTION WHICH ARE SIDE EFFECTS RELATED TO ANTICANCER DRUG TREATMENT | IL17A, ACHE, IL1B | CDC25B 174/4885CDC25A 97/4885IDO1 1918/4885 |
| US-20230372286-A1 | COMPOSITION COMPRISING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT, FOR PREVENTING OR AMELIORATING FATIGUE, CACHEXIA, PAIN, COGNITIVE DECLINE AND HEMATOPOIETIC STEM CELL REDUCTION WHICH ARE SIDE EFFECTS RELATED TO ANTICANCER DRUG TREATMENT | ACHE, NES, GSTO1 | CDC25B 356/4885CDC25A 236/4885IDO1 3195/4885 |
| US-20200155500-A1 | COMPOSITION FOR PREVENTING AND TREATING PANCREATITIS CONTAINING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT | AMY2A, PNLIP, SERPINB1 | CDC25B 1855/4885CDC25A 927/4885IDO1 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.